» Articles » PMID: 23152136

Proteomic Snapshot of Breast Cancer Cell Cycle: G1/S Transition Point

Overview
Journal Proteomics
Date 2012 Nov 16
PMID 23152136
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The biological processes that unfold during the G1-phase of the cell cycle are dependent on extracellular mitogenic factors that signal the cell to enter a state of quiescence, or commit to a cell-cycle round by passing the restriction point (R-point) and enter the S-phase. Unlike normal cells, cancer cells evolved the ability to evade the R-point and continue through the cell cycle even in the presence of extensive DNA damage or absence of mitogenic signals. The purpose of this study was to perform a quantitative proteomic evaluation of the biological processes that are responsible for driving MCF-7 breast cancer cells into division even when molecular checkpoints such as the G1/S R-point are in place. Nuclear and cytoplasmic fractions of the G1 and S cell-cycle phases were analyzed by LC-MS/MS to result in the confident identification of more than 2700 proteins. Statistical evaluation of the normalized data resulted in the selection of proteins that displayed twofold or more change in spectral counts in each cell state. Pathway mapping, functional annotation clustering, and protein interaction network analysis revealed that the top-scoring clusters that could play a role in overriding the G1/S transition point included DNA damage response, chromatin remodeling, transcription/translation regulation, and signaling proteins.

Citing Articles

Proteomic assessment of SKBR3/HER2+ breast cancer cellular response to Lapatinib and investigational Ipatasertib kinase inhibitors.

Karcini A, Mercier N, Lazar I Front Pharmacol. 2024; 15:1413818.

PMID: 39268460 PMC: 11391243. DOI: 10.3389/fphar.2024.1413818.


Proteomic insights into breast cancer response to brain cell-secreted factors.

Ahuja S, Lazar I Sci Rep. 2024; 14(1):19351.

PMID: 39169222 PMC: 11339284. DOI: 10.1038/s41598-024-70386-7.


Proteomic Assessment of SKBR3/HER2+ Breast Cancer Cellular Response to Lapatinib and Investigational Ipatasertib Kinase Inhibitors.

Karcini A, Mercier N, Lazar I bioRxiv. 2024; .

PMID: 38617302 PMC: 11014527. DOI: 10.1101/2024.04.02.587656.


Anti-inflammatory cytokine stimulation of HMC3 cells: Proteome dataset.

Ahuja S, Lazar I Data Brief. 2023; 49:109433.

PMID: 37554993 PMC: 10404857. DOI: 10.1016/j.dib.2023.109433.


MiR-5195-3p functions as a tumor suppressor in prostate cancer via targeting CCNL1.

Zeng X, Hu Z, Shen Y, Wei X, Gan J, Liu Z Cell Mol Biol Lett. 2022; 27(1):25.

PMID: 35260070 PMC: 8905902. DOI: 10.1186/s11658-022-00326-8.


References
1.
Verbeek B, Rijksen G, Vroom T . Grb2 overexpression in nuclei and cytoplasm of human breast cells: a histochemical and biochemical study of normal and neoplastic mammary tissue specimens. J Pathol. 1997; 183(2):195-203. DOI: 10.1002/(SICI)1096-9896(199710)183:2<195::AID-PATH901>3.0.CO;2-Y. View

2.
Vadlamudi R, Kumar R . Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal. 2007; 5:e004. PMC: 1876599. DOI: 10.1621/nrs.05004. View

3.
Wang G, Allis C, Chi P . Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends Mol Med. 2007; 13(9):363-72. DOI: 10.1016/j.molmed.2007.07.003. View

4.
Quinlan K, Verger A, Yaswen P, Crossley M . Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta. 2007; 1775(2):333-40. DOI: 10.1016/j.bbcan.2007.05.001. View

5.
Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel R, Bairoch A . ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 2003; 31(13):3784-8. PMC: 168970. DOI: 10.1093/nar/gkg563. View